Growth PotentialMarket penetration remains low, and Inspire Medical is expected to continue increasing its market share driven by favorable market trends.
GuidanceINSP reaffirmed its FY25 guidance, including sales of $900-910mn, GM of 84-86%, and diluted EPS of $0.40-0.50.
ValuationThe stock is trading at significantly lower multiples compared to its peers, suggesting it may be undervalued.